UPDATE: Jefferies Downgrades Pfizer on Challenges Ahead
In a report published Friday, Jefferies analyst Jeffrey Holford downgraded the rating on Pfizer (NYSE: PFE) from Buy to Hold, and lowered the price target from $32.00 to $30.00.
In the report, Jefferies noted, “Rising rate expectations had the expected impact on the sector, which has been driven by income investors over the past two years. Q2'13 earnings look tough in this context and we expect most companies to see some pressure. Novartis, Sanofi, Roche, Abbott, AbbVie and Bayer remain high conviction Buy ideas. We have downgraded Bristol-Myers and Pfizer to Hold in this report as part of our update today.”
Pfizer closed on Thursday at $28.44.
Latest Ratings for PFE
|Oct 2015||Morgan Stanley||Upgrades||Equal-weight||Overweight|
|Jun 2015||Jefferies||Initiates Coverage on||Overweight|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.